Eight Roads

Eight Roads is a global venture capital firm that operates as the proprietary investment arm of Fidelity International Limited. Founded in 1969, the firm has a strong presence in multiple regions, including Europe, Israel, China, India, Japan, and the United States. Eight Roads focuses on investing in early to growth-stage technology companies, particularly in sectors such as healthcare IT, financial services, software as a service (SaaS), and consumer technology. The firm typically invests between $1.29 million and $30 million, often taking minority stakes and seeking board representation in its portfolio companies. With offices in London, Hong Kong, and various cities across Asia, Eight Roads aims to support innovative companies poised for market success, leveraging its extensive network and industry expertise.

Umang Agarwal

Senior Associate

Aishwarya Arunkumar

Senior Associate

Hiroki Ashida

Senior Associate

Daniel Auerbach

Senior Managing Partner & Head of Global Ventures

Vytautas Balsys

Partner

Bence Banhalmi

Analyst

Helena Barman

Investor

Virginia Bassano

Investor

John Behrendt

Head of Principal Investments

Daniel Benjamin

Investor

Reda Bensaid

Analyst

Ayush Bhargava

Senior Associate

Shweta Bhatia

Partner

Rong Cai

Investment Director

Betty Cai

Partner

James Cartwright

Vice President

Arvind Chari

Vice President

Ted Chua

Senior Partner

Lucile Cornet

Partner

Richard Ding

Associate

Raj Dugar

Managing Partner, India

Martin Ericsson

vice_president

Sergio Ferrarini

Principal

Tamina Fogelberg

Investor

Luciana Germinario

Chief Finance Officer

Antonin Gury-Coupier

Investor

Davor Hebel

Managing Partner & Head of Europe

Brian Hershey

Associate

April Hu

Senior Associate

Allen Huo

Vice President

Momota Imai

Associate

Kristina Isherwood

Chief Financial Officer

Abhishek Jain

Senior Associate

Cyrus Jilla

Chief Executive Officer and President

Murata Junichi

Partner

Michiko Kohyama

Senior Associate

Shinichiro Komoto

Partner

Kavish Kothari

Principal

Lillian Li

Investor

Thomas Lin

Senior Associate

Xin Lin

Partner

Rebecca Lin

Senior Partner

Xin Liu

Partner

Allen Liu

Associate

James Lowther

Director

Jessica Lu

Vice President, Portfolio Management

Joshua Maxey

Senior Associate

Maneesh Menon

VP

Sophie Meralli

Senior Associate

Chersy Miao

Senior Associate

David Milstein

Managing Partner & Head of Japan

Shigeyuki Minoshiro

Associate

Moriam Mustapha

Senior Associate

Noriko Nakao

Senior Associate

Jens Neisius

vice_president

Angel Ng

Associate, Portfolio Management

Dave Ng

Head of Southeast Asia

Dan O'Toole

Vice President

Yosuke Ouchi

Vice President

Prem Pavoor

Partner and Head of India

Alexandra Prescot

Investor

Delphine Qiu

VP

Eyal Rabinovich

Investor

Vishap Rana

Senior Associate

Laura Salesse

Investor

Xiao Shen

Principal

Shawn Shen

Vice President

Lei Shi

Vice President

Prakhar Singh

Vice President

Michael Stephanblome

Venture Partner

Liena Suzuki

Vice President

Aditya Gurunath Systla

Partner

Emily Tam

Finance Director, Asia

Michael Treskow

Partner

Joseph Trinh

Chief Talent Partner

Jarlon Tsang

Managing Partner & Head of China

Ashish Venkataramani

Partner

Simon Wang

Associate

He Wang

Associate

Nancy Xu

Senior Associate

Cody Yin

Principal

Alston Zecha

Partner

Haoming Zhang

Senior Associate

Ju Zhang

Partner

Gordon Zhang

Vice President & Principal

Past deals in New Jersey

Spry

Series A in 2022
Spry is a cloud-based operating system that allows movement health professionals to collect and analyze patient data in real time.

Doceree

Series A in 2022
Doceree Inc operates a programmatic advertising platform specifically designed for physician engagement. Founded in 2019 and headquartered in Parsippany, New Jersey, with an additional office in New Delhi, India, the company provides a fully integrated ad exchange that facilitates data-driven marketing targeted exclusively at physicians. By offering access to physician-only platforms, Doceree enables media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals to effectively purchase advertising space and reach their desired audiences.

B-One

Venture Round in 2020
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.

B-One

Series A in 2018
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.

B-One

Venture Round in 2018
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.

Symbiomix Therapeutics

Venture Round in 2018
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly bacterial vaginosis (BV). Founded in 2012, the company is based in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut. Its lead product, Solosec (secnidazole), is a novel 5-nitroimidazole antibiotic designed for a one-time oral treatment of bacterial vaginosis, addressing a significant unmet need in women's healthcare. Symbiomix operates as a subsidiary of Lupin Inc. and is supported by prominent healthcare venture capital firms. The company aims to provide effective therapeutic options for gynecologic infections that have been historically overlooked.

Transave

Venture Round in 2006
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

Qumas

Venture Round in 2005
QUMAS delivers a closed-loop compliance model that standardizes and integrates the common elements of compliance tasks across the organization. Enterprises are able to effectively converge all of their compliance programs onto a single platform, radically reducing the cost of compliance and creating competitive advantage. With its proven track record in two of the of the most stringently regulated industries - financial services and life sciences - QUMAS has proven that it is best positioned to provide centralized compliance for any company, regardless of industry. Its solutions ensure corporate compliance with the full spectrum of global regulations.